Janssen Korea Faces Possible Six-Month Production Suspension
This article was originally published in PharmAsia News
Executive Summary
Johnson & Johnson's Janssen Korea unit has been found to have violated several manufacturing regulations during production of its Tylenol children's syrup that contained excessive amounts of acetaminophen API.